PD-(L)1, LAG-3, and TIM blockade

PD-(L)1 is not the only immune checkpoint inhibiting anti-cancer activity of the immune system. In particular, upregulation of LAG-3 and TIM have been associated with resistance to PD-(L)1 blockade [1]. In a first-in-human phase 1 trial, the anti-PD-1 antibody Sym021 was combined with either the anti-LAG-3 antibody Sym022 or the anti-TIM antibody Sym023 [2]. A total of 70 patients with a variety of heavily pretreated, advanced tumours was treated with either Sym021 monotherapy or one of the combinations at escalating doses up to 10-20 mg/kg every 2 week. Sym021 alone or in combination with Sym022 or Sym023 was well tolerated with an adverse event profile typical of immune checkpoint inhibitors. Anti-tumour activity was observed with either Sym021 alone or in combination. Further evaluation of the anti-tumour activity of the in select tumour types post-PD-(L)1 treatment is planned. Triplet (Sym021, Sym022, Sym023) dose escalation is ongoing.

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 25 November, 202024 November, 2020